EUVIMEDEUVIMED entdecken
Crossref

A novel imaging approach in hyperparathyroidism: [68Ga]Ga-Trivehexin PET/CT

Dilara Denizmen Zorba iD, Serkan Kuyumcu, Duygu Has Simsek, Emine Goknur Isik, Arzu Poyanli, Ayse Kubat Uzum, Fikret Buyukkaya, Semen Onder, Nihat Aksakal, Yalin Iscan, Zeynep Gozde Ozkan, Yasemin Sanli

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-07965-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Dilara Denizmen Zorba und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. dilaradenizmen@gmail.com. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Gallium Radioisotopes, Hyperparathyroidism. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the diagnostic performance of [68Ga]Ga-Trivehexin PET/CT for localizing hyperfunctioning parathyroid tissue in patients with primary hyperparathyroidism (PHPT) and to compare it with [99mTc]Tc-MIBI scintigraphy with SPECT/CT (MIBI scan). METHODS: In this retrospective study, patients with biochemically confirmed PHPT underwent both MIBI scan and [68Ga]Ga-Trivehexin PET/CT. Patient- and lesion-based detection rates were compared between modalities. [68Ga]Ga-Trivehexin PET/CT was acquired at approximately 40 ± 20 min after injection; delayed imaging at 80 ± 20 min was performed in a subset. Dynamic PET imaging was performed in three patients. Quantitative parameters, including SUVmax and lesion-to-background ratios, were recorded. Clinically relevant subgroups, including MEN-1-associated PHPT and persistent disease after surgery, were assessed. RESULTS: A total of 50 parathyroid-related lesions were evaluated in 38 patients. On patient-based analysis, MIBI scan and [68Ga]Ga-Trivehexin PET/CT correctly localized hyperfunctioning parathyroid tissue in 28 of 38 (74%) and 35 of 38 (92%) patients, respectively. On lesion-based analysis, [68Ga]Ga-Trivehexin PET/CT detected 49 of 50 lesions (98%), compared with 29 of 50 lesions (58%) detected by MIBI scan (P < 0.05). [68Ga]Ga-Trivehexin PET/CT demonstrated distinct focal uptake in 18 lesions with negative or equivocal MIBI findings. Dual-time-point imaging showed no significant differences in lesion SUVmax or lesion-to-background ratios between early and delayed scans. Dynamic imaging demonstrated a rapid increase in lesion contrast followed by a plateau, with no consistent improvement beyond approximately 25 min. CONCLUSION: [68Ga]Ga-Trivehexin PET/CT demonstrated higher detection rates than MIBI scan for localizing hyperfunctioning parathyroid tissue in PHPT, particularly in multiglandular and subcentimetric disease. Early acquisition appears sufficient, with limited added value of delayed imaging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyGallium RadioisotopesHyperparathyroidismHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultRadiopharmaceuticalsTechnetium Tc 99m Sestamibi

Stichwörter der Autor:innen

MEN1 syndromeParathyroid imagingPrimary hyperparathyroidism[68Ga]Ga-Trivehexin PET/CTαvβ6 integrin

Substanzen

Gallium RadioisotopesGallium-68RadiopharmaceuticalsTechnetium Tc 99m Sestamibi

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. dilaradenizmen@gmail.com.
  • Department of Nuclear Medicine, Adıyaman University Training and Research Hospital, Adiyaman, Turkey. dilaradenizmen@gmail.com.
  • Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Department of Radiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.
  • Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

ORCID-Profile: Dilara Denizmen Zorba

Zitieren

APA

Denizmen Zorba, D., Kuyumcu, S., Has Simsek, D., Isik, E. G., Poyanli, A., Kubat Uzum, A., Buyukkaya, F., Onder, S., Aksakal, N., Iscan, Y., Ozkan, Z. G., & Sanli, Y. (2026). A novel imaging approach in hyperparathyroidism: [68Ga]Ga-Trivehexin PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-07965-5

Vancouver

Denizmen Zorba D, Kuyumcu S, Has Simsek D, Isik EG, Poyanli A, Kubat Uzum A, et al. A novel imaging approach in hyperparathyroidism: [68Ga]Ga-Trivehexin PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-07965-5

BibTeX
@article{DenizmenZorba2026,
  author = {Denizmen Zorba, Dilara and Kuyumcu, Serkan and Has Simsek, Duygu and Isik, Emine Goknur and Poyanli, Arzu and Kubat Uzum, Ayse and Buyukkaya, Fikret and Onder, Semen and Aksakal, Nihat and Iscan, Yalin and Ozkan, Zeynep Gozde and Sanli, Yasemin},
  title = {A novel imaging approach in hyperparathyroidism: [68Ga]Ga-Trivehexin PET/CT},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-07965-5}
}
Kostenlos starten →